The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
04-Sep-23
Pending
$6.6 billion AUD
Target:
Liontown Resources Limited
Acquiror:
Albemarle Corporation
Advising Australian-based lithium company Liontown Resources Limited on its response to change of control proposals from Albemarle Corporation.
15-Aug-23
Pending
Undisclosed
Target:
ElectraMeccanica
Acquiror:
Tevva
Advising ElectraMeccanica, a North American designer and assembler of electric vehicles, on its all-stock merger with Tevva, a UK-based market leader in zero emission electric medium- and heavy-duty commercial vehicles
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
08-Aug-23
Pending
Undisclosed
Target:
Farmalider Group
Acquiror:
MCH
Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH
13-Jul-23
$224 million
Target:
Distribuidora Internacional Carmen SAU
Acquiror:
Diploma PLC
Advised Diploma PLC in the acquisition of Distribuidora Internacional Carmen SAU (“DICSA”), a market-leading distributor of fluid power solutions into the European aftermarket
01-Jun-23
$90.4 million
Target:
PCAS Canada Inc.
Acquiror:
DIC Corporation
Advised DIC Corporation, a Japanese specialty chemical company, on the acquisition of PCAS Canada Inc., a contract manufacturer of high-quality photoresist polymers, from PCAS SA, a French manufacturer of complex molecules for Life Sciences and Specialty Chemicals markets which is a majority-owned subsidiary of SK Capital-backed Seqens
27-Apr-23
$403 million
Target:
Distrelec BV
Acquiror:
RS Group plc
Advised RS Group plc on the acquisiton of Distrelec, a high-service, digital-led distributor of industrial MRO and electronic products
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
05-Apr-23
Pending
$185 million
Target:
Calibre Group’s QuadR Business
Acquiror:
WSP Global Inc.
Advising Calibre Group, an Australian diversified engineering group, on the sale of its Calibre QuadR business to WSP Global Inc., a leading global engineering and professional services firm
29-Mar-23
Pending
Undisclosed
Target:
Scandinavian Enviro Systems AB
Acquiror:
Antin Infrastructure Partners
Advising Enviro on the creation of the world’s first large-scale tire recycling group in a JV with Antin Infrastructure Partners, supported by Michelin
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
07-Mar-23
Undisclosed
Target:
David Brown Santasalo
Acquiror:
Stellex Capital Management
Advised N4 Partners on the sale of David Brown Santasalo (DBS), UK based industrial gear manufacturer, to Stellex Capital Management
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
09-Jan-23
Undisclosed
Target:
Schurter
Acquiror:
Capvis
Advising Capvis, a leading European mid-market investor, on the acquisition of Schurter, a global provider of components for circuit protection, connectors, switches and EMC products
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
28-Dec-22
Pending
Undisclosed
Target:
Eisai Distribution Co., Ltd.
Acquiror:
Yasuda Logistics Corporation
Advising Eisai, a Japanese pharmaceutical company, on the sale of Eisai Distribution, a 100% shares holding logistic subsidiary, to Yasuda Logistics Corporation, a Japanese logistic company conducting total logistic services such as Warehousing, Transportation, delivery and forwarding, and Port transportation business, etc.
23-Dec-22
Pending
Undisclosed
Target:
Exyte Management GmbH
Acquiror:
BDT Capital Partners LLC
Advising Stumpf Capital and Georg Stumpf on the sale of a minority interest in its wholly-owned company, Exyte, a global leader in the design, engineering and delivery of high-tech facilities, to funds affiliated with BDT Capital Partners
16-Dec-22
Pending
$617 million
Target:
Asterion Energies
Acquiror:
Repsol
Advising Asterion Industrial Partners, a leading independent investment management firm, on the sale of their portfolio company Asterion Energies, a leading Pan-European renewable energy platform with over 7.7 GW of Solar PV and Wind assets in Spain, Italy and France
30-Nov-22
Pending
Undisclosed
Target:
Calibre Group’s Built Environment Business
Acquiror:
Egis S.A.
Advised Calibre Group, a leading Australian provider of sustainable engineering solutions, on the sale of its Built Environment business to Egis S.A., a French headquartered global consulting and engineering services firm owned by Tikehau Capital and Caisse des Dépôts
28-Nov-22
Pending
$650 million
Target:
Brambles (CHEP China)
Acquiror:
Loscam Greater China
Adviser to Brambles on the merger of its China business (CHEP China) with Loscam Greater China
24-Nov-22
Pending
Undisclosed
Target:
Kyowa Kirin International’s established medicines business
Acquiror:
Grünenthal
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
18-Nov-22
Pending
$6.4 billion
Target:
OZ Minerals Limited
Acquiror:
BHP Group Limited
Advising Australian-based copper company OZ Minerals Limited, on its response to two change of control proposals from BHP Group Limited, the world’s largest diversified resources company
07-Nov-22
Undisclosed
Target:
Industrias Dolz
Acquiror:
Litens Automotive Group
Advised Realza Capital Partners, a leading Spanish private equity firm, on the disposal of Industrias Dolz, a leading global player in the manufacturing and distribution of water pumps for the independent automotive market (IAM).
27-Oct-22
$950 million
Target:
Minnesota Rubber and Plastics
Acquiror:
Trelleborg
Facilitated the sale of KKR’s portfolio company Minnesota Rubber and Plastics, a leading provider of materials science-based elastomer and thermoplastic solutions, to Trelleborg
13-Oct-22
$47 million
Target:
Electro Optic Systems
Acquiror:
Washington H. Soul Pattinson
Advised Electro Optic Systems, an Australian founded and listed aerospace and defence company, on agreeing financing terms with its largest shareholder, Washington H. Soul Pattinson